CAMBRIDGE, Mass. & VANCOUVER, B.C.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) has granted Tekmira Pharmaceuticals Corporation (TSX: TKM) a new target-specific InterfeRx™ license to discover, develop, and commercialize an RNAi therapeutic for the treatment of Ebola virus infection (TKM-Ebola). Detailed financial terms were not disclosed, but include royalties on sales of any resulting product under the licensing agreement.
